188Re-HEDP for palliation of pain from bone metastases

doi:10.3760/cma.j.issn.1673-422X.2013.11.019

Abstract

Abstract: ¹⁸⁸Re-HEDP is a bisphosphonate which preferentially incorporates into the sites of bone metastases. It interacts with bone metabolism, suppresses the activity of osteolysis, and gathers in tumor bone metastases. Recently, researches show that 188ReHEDP has some advantages for palliation of bone metastasisrelated pain because of its favorable physicochemical and biological characteristics. 188ReHEDP radioisotopes therapy will be an effective method for bone metastatic tumors.

Key words: Rhenium, Radiotherapy, Neoplasm metastasis, Bone neoplasms

NIU Yu-Jie, ZHANG He-Long. ¹⁸⁸Re-HEDP for palliation of pain from bone metastases[J]. Journal of International Oncology, 2013, 40(11): 864-866.

References

［1］ Sartor O, Hoskin P, Bruland OS. Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev, 2013, 39(1):18-26. ［2］Paes FM, Ernani V, Hosein P, et al. Radiopharmaceuticals: when and how to use them to treat metastatic bone pain. J Support Oncol, 2011, 9(6):197-205. ［3］Ebrahimi M, Assadi M, Rezaei MM. New bone pain palliation radiopharmaceuticals in Iran. Iran J Nucl Med, 2012, 20:135. ［4］Touchefeu Y, Franken P, Harrington KJ. Radiovirotherapy: principles and prospects in oncology. Curr Pharm Des, 2012, 18(22):3313-3320. ［5］Ogawa K, Washiyama K. Bone target radiotracers for palliative therapy of bone metastases. Curr Med Chem, 2012, 19(20):3290-3300. ［6］Turner JH. Outpatient therapeutic nuclear oncology. Ann Nucl Med, 2012, 26(4):289297. ［7］Pillai MR, Dash A, Knapp FF. Rhenium-188: availability from the (188)W/(188)Re generator and status of current applications. Curr Radiopharm, 2012, 5(3):228-243. ［8］Kalantari BA, Davarpanah MR, Ghannadi Maragheh M, et al. Synthesis and quality control of 188Re-HEDP and its biodisturbution studies in rats. Iran J Nucl Med, 2012, 20:133. ［9］Das T, Pillai MR. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol, 2013, 40(1):23-32. ［10］程爱萍，陈绍亮，陈曙光，等. 显像法分析188Re-HEDP在肿瘤骨转移患者体内的分布. 实用肿瘤杂志, 2009, 24(3):254-259. ［11］Liepe K, Geidel HH, Bergmann R, et al. Autoradiographic studies of rhenium-188hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer. Nucl Med Commun, 2009, 30(9):693-699. ［12］Cheng A, Chen S, Zhang Y, et al. The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases. Cancer Biother Radiopharm, 2011, 26(2):237-244. ［13］Chiacchio S, Mazzarri S, Lorenzoni A, et al. Radionuclide therapy and integrated protocols for bone metastases. Q J Nucl Med Mol Imaging, 2011, 55(4):431-447. ［14］Roqué I， Figuls M, Martinez-Zapata MJ, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev, 2011, 6(7):CD003347. ［15］Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun, 2007, 28(8):623-630. ［16］Biersack HJ, Palmedo H, Andris A, et al. Palliation and survival after repeated (188)ReHEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med, 2011, 52(11):1721-1726. ［17］Biersack HJ, Palmedo H, Andris A, et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer:a retrospective analysisReply. J Nucl Med, 2012, 53(8):1332. ［18］Lam MG, Bosma TB, van Rijk PP, et al. (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase Ⅰ safety and toxicity study. Eur J Nucl Med Mol Imaging, 2009, 36(9):1425-1433. ［19］Liepe K, Kotzerke J. Internal radiotherapy of painful bone metastases. Methods, 2011, 55(3):258-270.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[6]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[7]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[8]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[14]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[15]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.

¹⁸⁸Re-HEDP for palliation of pain from bone metastases

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments